The market’s optimistic assessment that inflation can easily be tamed is likely misplaced.
7 minute read
The market’s optimistic assessment that inflation can easily be tamed is likely misplaced.
7 minute read
Why we believe the biopharma industry should be able to adapt to drug pricing changes.
6 minute read
A turbulent year for both stocks and bonds may hold some silver linings.
32 minute listen
The case for small caps as the potential for recession looms.
5 minute read
A discussion on flow-driven strategies, which seek to find an edge in market events where money flows create dislocations.
5 minute read
With corporate performance proving resilient, the attractiveness of many equities market segments has improved during this year’s sell-off.
Read now
The traditional 60% stock/40% bond allocation suffered deep losses during the first half of 2022, but that doesn’t mean it’s time to give up on a diversified portfolio.
Listen now
The technology sector is adjusting to an era of higher discount rates and certain segments becoming more exposed to undulations in the broader economy.
Read now
Why we believe investors should resist the temptation to add credit risk too early.
Watch now
The inflation problem in emerging markets has become more complex to unravel and greater divergence between countries could emerge on the path to normalization.
Read now
A discussion on mortgage-backed securities in the latest episode of our Global Perspectives podcast series.
Listen now